SEC Filing Summary: ChromaDex Corp. (8-K)
Business Context and Reporting Period
This Form 8-K was filed by ChromaDex Corp. on December 3, 2014, reporting events that occurred on November 26, 2014. The filing details the disposition of the Company's holdings in NutriSci International, Inc. ("NS") immediately prior to NS's acquisition by Disani Capital Corp. Note: The input metadata references "Niagen Bioscience, Inc.," but the filing text explicitly identifies the registrant as ChromaDex Corp.
Key Financial Metrics and Transaction Details
- Asset Disposition: The Company converted 551,114 Series I Preferred Shares of NS into 2,204,456 Class A Common Shares of NS.
- Sale Proceeds: The Company sold the 2,204,456 Common Shares to Emprise Capital Corporation for a total purchase price of $749,514.80.
- Share Assignments: Prior to the sale, the Company assigned 108,676 Preferred Shares to Alpha Capital Anstalt and 10,868 Preferred Shares to Palladium Capital Advisors, LLC.
- Exchange Outcome: Upon the closing of the NS-Disani Amalgamation, the new holders (Alpha Capital, Palladium Capital, and Emprise Capital) received an aggregate of 4,560,474 units of Disani securities.
- Financial Statements: The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics for ChromaDex Corp. or NS.
Material Changes
The primary material change is the complete divestiture of ChromaDex Corp.'s equity interest in NutriSci International, Inc. The Company transitioned from holding preferred shares to receiving cash proceeds from the sale of converted common shares, effectively exiting its investment in NS prior to NS's amalgamation with Disani Capital Corp.
Guidance, Outlook, and Risks
The filing does not contain forward-looking guidance, management commentary on future operations, or specific risk factors related to the transaction beyond the standard disclosure that the summary is not complete. The transaction was executed pursuant to a Share Transfer Agreement and an amended Assignment and Escrow Agreement. Full details of these agreements are referenced as exhibits to the Company's Annual Report on Form 10-K for the fiscal year ended January 3, 2015.
Key Facts for Investor Verification
- Verify the final cash proceeds of $749,514.80 received from Emprise Capital Corporation.
- Confirm the conversion ratio of 1 Preferred Share to 4 Common Shares (551,114 to 2,204,456).
- Review the attached Press Release (Exhibit 99.1) for additional context on the disposition.
- Examine the full Share Transfer Agreement and Assignment and Escrow Agreement in the subsequent Form 10-K filing.
- Clarify the status of the 4,560,474 Disani units received by the assignees, as ChromaDex Corp. did not retain these units.